Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Clinical trial NCT03223103 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03223103
- Sponsor
- Adilia Hormigo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-01
- Primary completion
- 2029-05-12
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.